Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: Results of a multicenter, randomized, controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 7, 2001, Pages 965-972

  Testoni, P A ^a   Bagnolo, F ^e   Andriulli, A ^b   Bernasconi, G ^c   Crotta, S ^d   Lella, F ^e   Lomazzi, A ^f   Minoli, G ^g   Natale, C ^h   Prada, A ^e   Toti, G L ⁱ   Zambelli, A ^e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Policlinico San Marco   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e Ospedale Civile   (Italy)

^f Ospedale   (Italy)

^g VALDUCE HOSPITAL   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; OCTREOTIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ODDI SPHINCTER; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATITIS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0034954886     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01015.x     Document Type: Article

References (36)

1. ERCP and endoscopic biliary sphincterotomy-induced pancreatitis
2. Complications of endoscopic sphincterotomy: A prospective study with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts
3. Post-ERCP pancreatitis: Randomized, prospective study comparing a low- and high-osmolality contrast agent
4. Endoscopic sphincterotomy-induced pancreatitis: Increased risk associated with nondilated bile duct and sphincter of Oddi dysfunction
5. Complications of endoscopic biliary sphincterotomy
6. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography
7. Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis
8. Major early complications from diagnostic and therapeutic ERCP, a prospective multicenter study
9. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study
10. ERCP and endoscopic sphincterotomy-induced pancreatitis
11. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction
12. Endoscopic pancreatic sphincterotomy: Indications, outcome, and a safe stentless technique
13. Pharmacologic treatment can prevent pancreatic injury after ERCP. a meta-analysis
14. Use of corticosteroids in the prevention of post-ERCP pancreatitis
15. Does the somatostatin analogue octreotide protect against ERCP-induced pancreatitis?
16. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis
17. The use of a long-acting somatostatin analogue (Octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy
18. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla
19. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes
20. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis
21. Clinical outcome of post-ERCP pancreatitis: Relationship to history of previous pancreatitis
22. Endoscopic sphincterotomy complications and their management: An attempt at consensus
23. Dysmotility disturbances of the biliary tract; classification, diagnosis, and treatment
24. Frequency of abnormal sphincter of Oddi manometry compared with the clinical suspicion of sphincter of Oddi dysfunction
25. Evaluation of post-ERCP pancreatitis: Potential causes noted during controlled study of different contrast media
26. Does common bile duct diameter influence the risk of post-sphincterotomy complications?
27. Twenty-four-hour pain associated with hyperamylasemia higher than five times the upper normal limit is the most reliable indicator of post-ERCP pancreatitis
28. A clinically-based classification system for acute pancreatitis
29. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy
30. Gabexate in the prevention of post-ERCP pancreatitis: Should we be inhibited by the cost?
31. Economic analysis of gabexate mesilate in post-ERCP pancreatitis
32. Effect of somatostatin analog octreotide on human sphincter of Oddi
33. Effect of octreotide on sphincter of Oddi motility in patients with acute recurrent pancreatitis: A manometric study
34. Ultrasonography-secretin test pattern after acute administration of octreotide in healthy persons and in patients with recurrent acute pancreatitis
35. Effect of octreotide, a long-acting somatostatin analogue, on plasma amino acid uptake by the pancreas
36. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide